The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Jinling Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.90% CNY6.96
America/New_York / 30 apr 2024 @ 03:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 328.60 mill |
| EPS: | 0.220 |
| P/E: | 31.64 |
| Earnings Date: | Apr 29, 2024 |
| SharesOutstanding: | 621.93 mill |
| Avg Daily Volume: | 7.20 mill |
| RATING 2024-04-30 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Strong Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.88x |
| Company: PE 31.64 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.69x |
| Company: PE 31.64 | industry: PE 45.57 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY6.76 (-2.92%) CNY-0.203 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 6.78 - 7.14 ( +/- 2.59%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY6.96 (1.90% ) |
| Volume | 9.50 mill |
| Avg. Vol. | 7.20 mill |
| % of Avg. Vol | 132.02 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 000919.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
000919.SZ
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China. The company offers Mailuoning injection for the treatment of thrombo-occlusive vasculitis, arteriosclerotic occlusive disease, cerebral thrombosis and sequelae, multiple arteritis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; and lentinan injection for treatment of malignant tumors. It also provides medical health care services. Jinling Pharmaceutical Company Limited is based in Nanjing, China.